- $489.43m
- $601.01m
- $297.18m
Evolus Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Evolus Q3 Net Income USD -19.17 Million
Brief: Evolus Announces EU Approval Of Estyme® Injectable Hyaluronic Acid Gels
Brief: Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals
Evolus climbs on surprise quarterly profit
Evolus Inc reports results for the quarter ended in June - Earnings Summary
Brief: Evolus Q2 Adjusted Gross Margin 71.5%
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rival
Evolus Inc expected to post a loss of 5 cents a share - Earnings Preview
AbbVie lifts annual profit forecast on strong immunology drug sales (updated)
AbbVie lifts annual profit forecast on strong immunology drug sales
Brief: Evolus Announces Appointment Of Albert White III To Board Of Directors
Brief: Evolus Announces Submission Of Premarket Approval Application To The U.S. Food And Drug Administration For First Two Evolysse™ Dermal Filler Products
Evolus Inc reports results for the quarter ended in March - Earnings Summary
Brief: Evolus Q1 Adjusted Gross Margin 69.5%
Evolus Inc expected to post a loss of 10 cents a share - Earnings Preview
AbbVie lifts profit forecast after Skyrizi sales beat expectations (updated)
AbbVie raises annual profit forecast on strong Skyrizi sales